TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34775948
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (COT)
Study: 33180007
Drug: Acute beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute beetroot juice supplementation (70 mL, 6.4 mmol NO3‐)
Study: 32808409
Drug: Active soft
Normalized name: Nature's Way Petadolex Pro-Active Softgels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active soft tissue therapy (stretching exercise + active soft tissue therapy)
Study: 35086112
Drug: 0.35% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35% levobupivacaine (7 mL/h for 48 hours)
Study: 34601736
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 800 mg
Study: 34601736
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 800 mg and Placebo
Study: 36100943
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality therapy (7 sessions within 12 weeks)
Study: 34202578
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU oral vitamin D3
Study: 34202578
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU oral vitamin D3 (standard control)
Study: 35239819
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation (MED)
Study: 33990145
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CON)
Study: 35910820
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral ivermectin plus zinc sulfate for 3 days
Study: 33376119
Drug: Experimental calculus
Normalized name: Anamirta cocculus fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental calculus disruption solution (EXP‐955)
Study: 36748363
Drug: CT-P17 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P17 (40 mg/0.4 ml)
Study: 36748363
Drug: EU-adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-adalimumab (40 mg)
Study: 33855449
Drug: Fosfomycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (100 mg/kg IV q12h for 48h, then converted to oral therapy at the same dose)
Study: 33989086
Drug: Home medication
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home medication review by community pharmacists (HMR-CP)
Study: 36216274
Drug: Daily Partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Partial Breast Irradiation (PBI) - 35 Gy in 10 daily fractions, with a 9 Gy boost in 3 fractions for patients with close margins
Study: 36216274
Drug: Daily Partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Partial Breast Irradiation (PBI)
Study: 32700191
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusions of felbinac trometamol (11.78–377.00 mg)
Study: 32700191
Drug: Multiple intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravenous infusions of felbinac trometamol (47.13–188.50 mg)
Study: 32700191
Drug: Felbinac trometamol
Normalized name: felbinac
DrugBank: Felbinac (DB07477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbinac trometamol (various doses)
Study: 35500171
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with PPIs
Study: 35500171
Drug: Aspirin without
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin without PPIs
Study: 34214585
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg tablets once daily for 12 weeks
Study: 34214585
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily for 12 weeks
Study: 34416879
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg daily for six months)
Study: 33028425
Drug: Targeted normothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted normothermia and active treatment of fever (≥ 37.8 °C)
Study: 36059956
Drug: Prophylactic TXA
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic TXA (10 mg/kg followed by 5 mg/kg/h) with TEG‐guided hemostatic algorithm
Study: 32817692
Drug: Tsima intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tsima intervention (HIV treatment as prevention)
Study: 32060155
Drug: Dexamethasone-based elixir
Normalized name: Dexamethasone Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone-based elixir mouthwash (10 mL 0.1 mg/mL; swish for 2 min and spit, four times daily for 9 weeks)
Study: 32060155
Drug: Dexamethasone-based elixir
Normalized name: Dexamethasone Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone-based elixir mouthwash
Study: 36506010
Drug: NAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC treatment of SLA-stimulated PBMCs
Study: 32474302
Drug: Conventional lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lipid-lowering therapy (pitavastatin monotherapy)
Study: 32474302
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 3, HDL-C ≥53.6 mg/dL)
Study: 32474302
Drug: Pitavastatin +
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin + ezetimibe therapy
Study: 36908150
Drug: Pitavastatin monotherapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin monotherapy
Study: 33339359
Drug: Caffeine-containing energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing energy shot (CAF, 5 mg/kg)
Study: 32721973
Drug: Diuretic efficiency
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic efficiency
Study: 36433919
Drug: Intensive SBP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive SBP treatment (target 110 to <130 mmHg)
Study: 36433919
Drug: Standard SBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SBP treatment (target 130 to <150 mmHg)
Study: 39016010
Drug: Standard SBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SBP treatment
Study: 33225631
Drug: Anifrolumab 1000
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 1000 mg IV every 4 weeks, reduced to 300 mg every 4 weeks based on benefit/risk profile
Study: 35182101
Drug: Lean pork
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean pork (156 g day-1)
Study: 35182101
Drug: Chicken (active-control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken (active-control, 156 g day-1)
Study: 34910595
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.5 mg/kg, twice daily for 2 months
Study: 35182418
Drug: MIB-626 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIB-626 1000 mg once daily
Study: 35182418
Drug: MIB-626 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIB-626 1000 mg twice daily
Study: 32816504
Drug: T-SIB (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-SIB (Treatment for Self-Injurious Behaviors)
Study: 33264516
Drug: Bimagrumab 3
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 3 mg/kg
Study: 35679043
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation treatment (up to 11 counseling sessions with free medications)
Study: 35679043
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (up to 4 counseling sessions with medication advice)
Study: 36383611
Drug: Colchicine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.2 mg on day 1 followed by 0.6 mg daily for 13 days)
Study: 32249621
Drug: Kd70 QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kd70 QW (carfilzomib 70 mg/m2 once-weekly plus dexamethasone)
Study: 32249621
Drug: Kd27 BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kd27 BIW (carfilzomib 27 mg/m2 twice-weekly plus dexamethasone)
Study: 38575409
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs)
Study: 32597737
Drug: Integrative Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Cognitive Affective Therapy (ICAT-BED)
Study: 32597737
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy Guided Self-Help (CBTgsh)
Study: 34288280
Drug: ABCT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCT + treatment as usual (TAU)
Study: 33962825
Drug: Higher cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cancer anxiety, being male, recent screening, family history of breast/prostate cancer, independence in activities of daily living
Study: 36241697
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with CHOP (plus rituximab in CD20-positive lymphomas)
Study: 34499135
Drug: Telecare case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telecare case management program (weekly case management from a nurse via telephone and weekly video messages for 3 months)
Study: 34499135
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly social telephone calls)
Study: 32672795
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, or 10 mg/kg every 3 weeks)
Study: 34484887
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M)
Study: 32340375
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily water intake (two additional 550 mL bottles of water consumed daily)
Study: 33471487
Drug: ACE+TUDCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE+TUDCA treatment for 8 weeks
Study: 33471487
Drug: Sham ACE+TUDCA
Normalized name: TUDCA
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ACE+TUDCA treatment for 8 weeks
Study: 35432194
Drug: Exenatide treatment
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide treatment
Study: 34867786
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet plus placebo injections
Study: 34265218
Drug: Multimodal prehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal prehabilitation including nutritional supplements (fish oil with vitamin D3 + whey protein with leucine), exercise and relaxation
Study: 32683400
Drug: Insulin‐dependent Diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐dependent Diabetes Mellitus (IDDM)
Study: 32683400
Drug: Positive GAD65
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive GAD65 antibodies
Study: 35688358
Drug: Pimitespib 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimitespib 160 mg/day
Study: 34491652
Drug: Compound flumetasone
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound flumetasone ointment, applied twice a day for 3 weeks
Study: 34018445
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% cream
Study: 33421039
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group discussion session twice a week for 1 month)
Study: 32410200
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (low‐level laser therapy) including red light (660 nm), infrared light (840 nm), and infrared laser applied on the first postoperative day
Study: 35122442
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using a diode laser, 808 nm, 250 mW; 16.25 J; 32.5 J cm-2
Study: 35122442
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic gel (Benzocaine 20%)
Study: 34754346
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% 15 ml plus ketamine 0.5 mg/kg (LK group)
Study: 34754346
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% 15 ml plus 5 ml normal saline (L group)
Study: 34233331
Drug: ACCEPT® (Additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCEPT® (Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment) for 3 months with standard oncological care (SOC)
Study: 36331570
Drug: Accelerated strategy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated strategy of renal-replacement therapy (RRT) initiation
Study: 36331570
Drug: Standard strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard strategy of renal-replacement therapy (RRT) initiation
Study: 34806624
Drug: Ultrasound-guided botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided botulinum toxin injection (50 units of botulinum toxin type A)
Study: 34806624
Drug: Balloon catheter
Normalized name: Paclitaxel coated angioplasty balloon catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon catheter dilatation therapy (five times per week for two weeks)
Study: 32034202
Drug: Inhaled milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled milrinone (5 mg) by mesh nebulization
Study: 32034202
Drug: Inhaled milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled milrinone (5 mg) by jet nebulization
Study: 35739713
Drug: True air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: True air purification treatment
Study: 35739713
Drug: Sham air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham air purification treatment
Study: 33037810
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate 50 mg daily plus conventional hospital management
Study: 32404731
Drug: Immunotherapy (2011-2013)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (2011-2013)
Study: 32404731
Drug: Immunotherapy (2014)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (2014)
Study: 32429720
Drug: Postoperative inosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative inosine pranobex immunotherapy
Study: 32429720
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative immunotherapy
Study: 36207508
Drug: Simultaneous initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Simultaneous initiation of lixisenatide and basal insulin (BI)
Study: 36207508
Drug: Sequential initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential initiation of lixisenatide and basal insulin (BI)
Study: 32325856
Drug: Yeast beta-glucan
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast beta-glucan (YBG) 250 mg/day
Study: 32862111
Drug: IFN β‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN β‐1b (250 mcg subcutaneously every other day for two consecutive weeks)
Study: 32862111
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (national protocol medications: lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7–10 days)
Study: 35123553
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1
Study: 34927213
Drug: Continuous orthodontic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous orthodontic force of 150 g applied for 8 weeks, reactivated after 28 days.
Study: 34927213
Drug: Intermittent orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent orthodontic force (21 days on, 7 days off) of 150 g applied for 8 weeks.
Study: 35384391
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplant (FMT) capsules, administered 5 times over 3 weeks
Study: 35384391
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplant (FMT) capsules
Study: 33234419
Drug: Sweet orange
Normalized name: sweet orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet orange inhalation
Study: 33234419
Drug: Damask rose
Normalized name: damask rose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Damask rose inhalation
Study: 35142713
Drug: Metformin (1561
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1561 ± 470 g·d‐1)
Study: 35142713
Drug: Resistance Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Training + Metformin (RT + MET)
Study: 32743852
Drug: Lipid-lowering drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drugs
Study: 32500569
Drug: Intra-operative fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative fibrinogen concentrate 30 mg.kg-1 (maximum 2 g)
Study: 32219329
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg (up-titration to 50 mg at week 6)
Study: 35152579
Drug: Bloodletting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bloodletting therapy combined with auricular point sticking, given once every two days for 4 weeks.
Study: 35152579
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of levocetirizine hydrochloride, 10 mL once daily for 4 weeks.
Study: 33022987
Drug: Helianthus tuberosus
Normalized name: Helianthus Tuberosus Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helianthus tuberosus intake in the morning (5 g/day before breakfast)
Study: 33022987
Drug: Helianthus tuberosus
Normalized name: Helianthus Tuberosus Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helianthus tuberosus intake in the evening (5 g/day before dinner)
Study: 32149822
Drug: Preoperative prognostic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative prognostic factors including carbohydrate antigen 19-9, neoadjuvant treatment, tumor size, age, facility type, Charlson/Deyo score, primary site, and sex.
Study: 32612213
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-inflammatory diet and cannabinoids
Study: 35222266
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum folate concentrations (Q4≥33.0 ng/ml)
Study: 35222266
Drug: Highest Ca/Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest Ca/Mg ratio quartile (≥5.02)
Study: 35902851
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) in form of written information material
Study: 34806975
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (ceftazidime and tobramycin for 14 days, inhaled colistimethate sodium for 3 months)
Study: 34806975
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (ciprofloxacin for 3 months, inhaled colistimethate sodium for 3 months)
Study: 32317585
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg, oral, two times daily)
Study: 35784742
Drug: LY06006 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY06006 60 mg
Study: 38643086
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT) alone
Study: 35596030
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 and 15 mg pooled)
Study: 34826124
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg Q2W
Study: 34192387
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg Q2W to CZP 200 mg Q2W
Study: 34192387
Drug: Placebo to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to CZP 200 mg Q2W
Study: 34192387
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg Q2W (escape arm)
Study: 32932231
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (300 mg caffeine, 6 g sugars)